Hormone drugs associated with higher risk of brain tumor
A recent study highlights an association between prolonged use (defined as a year or more) of certain progestogen hormone drugs and an increased risk of developing intracranial meningioma, a type of brain tumor. Progestogens, similar to the natural hormone progesterone, are commonly used for various gynecological conditions and hormone therapy. While factors like older age, female sex, and exposure to specific high-dose progestogens are known to elevate meningioma risk, this study aimed to evaluate the individual risk associated with various progestogens. Analyzing data from over 18,000 women who underwent meningioma surgery, researchers found that prolonged use of medrogestone, medroxyprogesterone acetate injection, and promegestone correlated with increased meningioma risk. Conversely, no elevated risk was observed with shorter-term use or with certain other progestogens. Given the widespread use of certain progestogens like medroxyprogesterone acetate for birth control, the potential impact on meningioma rates could be significant. The study underscores the need for further research to better understand and mitigate this risk.
Source: asamonitor.pub/3TJPw8L